A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer

Hideaki Bando, Yoshinori Kagawa, Takeshi Kato, Kiwamu Akagi, Tadamichi Denda, Tomohiro Nishina, Yoshito Komatsu, Eiji Oki, Toshihiro Kudo, Hiroshi Kumamoto, Takeharu Yamanaka, Takayuki Yoshino

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: OncoBEAMTM RAS CRC kit using BEAMing technology is a circulating tumour DNA (ctDNA) test for detecting plasma RAS mutational status in metastatic colorectal cancer (mCRC). We conducted a multicentre, prospective study to investigate the concordance of the RAS mutational status between plasma ctDNA and tumour tissue DNA. Methods: mCRC patients without prior anti-EGFR antibodies or regorafenib treatment were enroled. Plasma- and tissue-based RAS mutational status were determined by BEAMing, respectively. Results: A total of 280 patients from eight institutions were eligible. The overall agreement between plasma- and tissue-based analyses was 86.4%, with a positive percent agreement of 82.1% and negative percent agreement of 90.4%. From logistic regression analysis, lung metastasis alone indicated the most significant factor associated with discordance. The agreement between plasma- and tissue-based analyses was 64.5% in patients with lung metastasis alone (n = 31) indicating lower amount of ctDNA. Among the cases with lung metastasis alone, all plasma- and tissue-based analyses were perfectly concordant in cases with ≥20 mm of maximum lesion diameter or ≥10 lesions. Conclusion: The clinical validity of OncoBEAMTM RAS CRC kit was confirmed. Careful attention should be paid for mCRC patients with lung metastases alone having fewer metastases or smaller diameter lesions.

Original languageEnglish
Pages (from-to)982-986
Number of pages5
JournalBritish journal of cancer
Volume120
Issue number10
DOIs
Publication statusPublished - May 14 2019

Fingerprint

Multicenter Studies
Colorectal Neoplasms
Prospective Studies
Mutation
Neoplasm Metastasis
DNA
Neoplasms
Lung
Anti-Idiotypic Antibodies
Logistic Models
Regression Analysis
Technology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. / Bando, Hideaki; Kagawa, Yoshinori; Kato, Takeshi; Akagi, Kiwamu; Denda, Tadamichi; Nishina, Tomohiro; Komatsu, Yoshito; Oki, Eiji; Kudo, Toshihiro; Kumamoto, Hiroshi; Yamanaka, Takeharu; Yoshino, Takayuki.

In: British journal of cancer, Vol. 120, No. 10, 14.05.2019, p. 982-986.

Research output: Contribution to journalArticle

Bando, H, Kagawa, Y, Kato, T, Akagi, K, Denda, T, Nishina, T, Komatsu, Y, Oki, E, Kudo, T, Kumamoto, H, Yamanaka, T & Yoshino, T 2019, 'A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer', British journal of cancer, vol. 120, no. 10, pp. 982-986. https://doi.org/10.1038/s41416-019-0457-y
Bando, Hideaki ; Kagawa, Yoshinori ; Kato, Takeshi ; Akagi, Kiwamu ; Denda, Tadamichi ; Nishina, Tomohiro ; Komatsu, Yoshito ; Oki, Eiji ; Kudo, Toshihiro ; Kumamoto, Hiroshi ; Yamanaka, Takeharu ; Yoshino, Takayuki. / A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. In: British journal of cancer. 2019 ; Vol. 120, No. 10. pp. 982-986.
@article{7000e77058bb495e96ff08740420bd22,
title = "A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer",
abstract = "Background: OncoBEAMTM RAS CRC kit using BEAMing technology is a circulating tumour DNA (ctDNA) test for detecting plasma RAS mutational status in metastatic colorectal cancer (mCRC). We conducted a multicentre, prospective study to investigate the concordance of the RAS mutational status between plasma ctDNA and tumour tissue DNA. Methods: mCRC patients without prior anti-EGFR antibodies or regorafenib treatment were enroled. Plasma- and tissue-based RAS mutational status were determined by BEAMing, respectively. Results: A total of 280 patients from eight institutions were eligible. The overall agreement between plasma- and tissue-based analyses was 86.4{\%}, with a positive percent agreement of 82.1{\%} and negative percent agreement of 90.4{\%}. From logistic regression analysis, lung metastasis alone indicated the most significant factor associated with discordance. The agreement between plasma- and tissue-based analyses was 64.5{\%} in patients with lung metastasis alone (n = 31) indicating lower amount of ctDNA. Among the cases with lung metastasis alone, all plasma- and tissue-based analyses were perfectly concordant in cases with ≥20 mm of maximum lesion diameter or ≥10 lesions. Conclusion: The clinical validity of OncoBEAMTM RAS CRC kit was confirmed. Careful attention should be paid for mCRC patients with lung metastases alone having fewer metastases or smaller diameter lesions.",
author = "Hideaki Bando and Yoshinori Kagawa and Takeshi Kato and Kiwamu Akagi and Tadamichi Denda and Tomohiro Nishina and Yoshito Komatsu and Eiji Oki and Toshihiro Kudo and Hiroshi Kumamoto and Takeharu Yamanaka and Takayuki Yoshino",
year = "2019",
month = "5",
day = "14",
doi = "10.1038/s41416-019-0457-y",
language = "English",
volume = "120",
pages = "982--986",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer

AU - Bando, Hideaki

AU - Kagawa, Yoshinori

AU - Kato, Takeshi

AU - Akagi, Kiwamu

AU - Denda, Tadamichi

AU - Nishina, Tomohiro

AU - Komatsu, Yoshito

AU - Oki, Eiji

AU - Kudo, Toshihiro

AU - Kumamoto, Hiroshi

AU - Yamanaka, Takeharu

AU - Yoshino, Takayuki

PY - 2019/5/14

Y1 - 2019/5/14

N2 - Background: OncoBEAMTM RAS CRC kit using BEAMing technology is a circulating tumour DNA (ctDNA) test for detecting plasma RAS mutational status in metastatic colorectal cancer (mCRC). We conducted a multicentre, prospective study to investigate the concordance of the RAS mutational status between plasma ctDNA and tumour tissue DNA. Methods: mCRC patients without prior anti-EGFR antibodies or regorafenib treatment were enroled. Plasma- and tissue-based RAS mutational status were determined by BEAMing, respectively. Results: A total of 280 patients from eight institutions were eligible. The overall agreement between plasma- and tissue-based analyses was 86.4%, with a positive percent agreement of 82.1% and negative percent agreement of 90.4%. From logistic regression analysis, lung metastasis alone indicated the most significant factor associated with discordance. The agreement between plasma- and tissue-based analyses was 64.5% in patients with lung metastasis alone (n = 31) indicating lower amount of ctDNA. Among the cases with lung metastasis alone, all plasma- and tissue-based analyses were perfectly concordant in cases with ≥20 mm of maximum lesion diameter or ≥10 lesions. Conclusion: The clinical validity of OncoBEAMTM RAS CRC kit was confirmed. Careful attention should be paid for mCRC patients with lung metastases alone having fewer metastases or smaller diameter lesions.

AB - Background: OncoBEAMTM RAS CRC kit using BEAMing technology is a circulating tumour DNA (ctDNA) test for detecting plasma RAS mutational status in metastatic colorectal cancer (mCRC). We conducted a multicentre, prospective study to investigate the concordance of the RAS mutational status between plasma ctDNA and tumour tissue DNA. Methods: mCRC patients without prior anti-EGFR antibodies or regorafenib treatment were enroled. Plasma- and tissue-based RAS mutational status were determined by BEAMing, respectively. Results: A total of 280 patients from eight institutions were eligible. The overall agreement between plasma- and tissue-based analyses was 86.4%, with a positive percent agreement of 82.1% and negative percent agreement of 90.4%. From logistic regression analysis, lung metastasis alone indicated the most significant factor associated with discordance. The agreement between plasma- and tissue-based analyses was 64.5% in patients with lung metastasis alone (n = 31) indicating lower amount of ctDNA. Among the cases with lung metastasis alone, all plasma- and tissue-based analyses were perfectly concordant in cases with ≥20 mm of maximum lesion diameter or ≥10 lesions. Conclusion: The clinical validity of OncoBEAMTM RAS CRC kit was confirmed. Careful attention should be paid for mCRC patients with lung metastases alone having fewer metastases or smaller diameter lesions.

UR - http://www.scopus.com/inward/record.url?scp=85064753831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064753831&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0457-y

DO - 10.1038/s41416-019-0457-y

M3 - Article

C2 - 31015557

AN - SCOPUS:85064753831

VL - 120

SP - 982

EP - 986

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -